Change in the amount of Revenio Group Corporation’s treasury shares

Revenio Group Corporation has today transferred a total of 2,072 of its treasury shares (REGV1) to individuals included in Revenio’s share-based incentive plans RSP 2021–2023 and RSP 2024–2026.

The transfer of shares is based on the decision announced by Revenio's Board of Directors in a stock exchange release on February 21, 2025, to grant the company’s own shares held by the company due to the fulfillment of the performance criteria of the RSP 2024–2026 share-based incentive plan and in accordance with the terms of the RSP 2021–2023 share-based incentive plan.

After the transfer, Revenio Group Corporation holds a total of 82,237 of its treasury shares.

For further information, please contact
Robin Pulkkinen, CFO, tel.  +358 50 505 9932
[email protected]

Distribution
Nasdaq Helsinki Oy
Principal media
www.reveniogroup.fi/en 

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.